Nalaganje...
Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor
The majority of gastrointestinal stromal tumors (GIST) harbor an activating mutation in either the KIT or PDGFRA receptor tyrosine kinases. Approval of imatinib, a KIT/PDGFRA tyrosine kinase inhibitor (TKI), meaningfully improved the treatment of advanced GIST. Other TKIs subsequently gained approva...
Shranjeno v:
| izdano v: | Front Oncol |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Frontiers Media S.A.
2021
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8313277/ https://ncbi.nlm.nih.gov/pubmed/34322383 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.672500 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|